CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotech has plans to work with the Mexican National Institutes of Health on a trial of leronlimab for severe coronavirus patients in the country.
Pourhassan says the initial trial is expected to include about 30 patients. After that, there is potential for the NIH of Mexico to get involved in the group's two larger coronavirus trials.
Price: 2.96 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE
CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan and Chief Science Officer Dr Jacob Lalezari tells Proactive the biotech is set to submit a clinical trial design to the FDA to compare the effectiveness of leronlimab versus Gildead's remdesivir, and in combination with remdesivir for the treatment...
Director Interviews
CytoDyn partner to offer free testing for coronavirus-linked...
Director Interviews
CytoDyn shares manuscript of potential coronavirus treatment to...
Retail & consumer
Prev article
